Close
CDMO Safety Testing 2026
Novotech

SmartLabs, a First-of-Its-Kind Laboratory-as-a-Service, Expands Nationally with CA Location

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...
- Advertisement -

Boston-based Laboratory-as-a-Service (LaaS) leader, SmartLabs, announced a national expansion with the addition of 80,000 square feet in South San Francisco, California. Building upon its continued success in Massachusetts, SmartLabsโ€™s new San Francisco laboratories will deliver high quality, turnkey R&D space and operations support for companies of varying sizes. Fueling the expansion efforts, the company also announced $36 million in Series A funding. The funding round was led by Conversion Venture Capital (CVC2), ArrowMark partners, and Breeds Hill Capital and will be used to expand nationally while investing in the companyโ€™s industry leading proprietary modular lab design and construction capabilities.

โ€œUntil now, creating top-quality R&D workspaces and the needed operations infrastructure has been too labor-intensive and cost-prohibitive for many companies. By offering enterprise quality labs with customizable layouts, we can reduce start-up costs by 90 percent and create more time for teams to be focused and productive,โ€ said Amrit Chaudhuri, CEO and co-founder of SmartLabs. โ€œWe have had an overwhelmingly positive response in Massachusetts and many of our existing lab spaces are already at capacity. This infusion of funding is yet another validation of the importance of our offering. We are eager to bring our productive, enjoyable spaces to the West Coast.โ€

SmartLabs currently offers flexible lab and office spaces that are customizable to accommodate research groups from fewer than 10 to more than 100 employees in three locations in Massachusetts. SmartLabsโ€™s new South San Francisco program, located off route 101 at 2 Tower Place, will feature:

  • Rapid launch capabilities allowing companies to begin experiments within 2-4 weeks of move in.
  • Lab support spaces including Tier 3 data rooms, waste storage and lab services (glass wash, piped gases, vacuum, etc.).
  • On-site staff supporting facilities, lab operations, EHS, IT, waste management, shipping and receiving, and glass wash.
  • Access to common operations support spaces including reception, conference rooms, lecture halls, event spaces, security, and shipping and receiving.
  • On-site amenities designed to ensure employee satisfaction including campus shuttles, a world class gym, and complimentary food and beverage program.

โ€œWhile we are in our formative stages of development, I want to be spending our resources on science. I don’t want to be burdened with the challenges of managing a facility,โ€ said Dan Passeri, CEO of Cue Biopharma, a company that has been part of SmartLabs since their inception in 2015.

SmartLabs reduces the time and cost of launching a research program. Teams of 10, 20, 40, and larger can launch rapidly and save up to 45% in the first three years, maximizing a companyโ€™s capital efficiency.

Latest stories

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...

AstraZeneca UK Investment Resumes with ยฃ300m Commitment

In a reversal of its earlier stance, AstraZeneca has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป